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Abstract
BrachyView is a novel in-body imaging system, aimed to accurately localise brachytherapy sources
using high-resolution pixelated silicon detectors and a pinhole collimator. In the recent years, many
research projects have studied the different possibilities for real-time, intra-operative, dynamic dose
treatment planning to increase the quality of brachytherapy implants. The capabilities of this pinhole
camera were tested through a proof of concept study using four active seeds. A more clinically realistic
scenario, using twenty active seeds implanted in a PMMA phantom, was the clear next step. To further
imitate a clinical scenario, 20 seeds were implanted and imaged using a single pinhole lead collimator
with a diameter of 400 μm. BrachyView was successful at locating the seeds within 1-2 mm of their
expected positions which was verified via co-registration with a full clinical post-implant CT scan with
0.8 mm width.
The first BrachyView prototype to feature a triple-chip detector embedded within a tungsten
collimator with three single cone pinholes was used to localise 30 active seeds embedded within 11
needles, implanted in a soft gel prostate phantom, under ultrasound guidance. For verification, a full
post implant CT was also performed. The BrachyView was able to accurately resolve the all the seeds
with a maximum discrepancy of 1.78 mm
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Chapter One: Introduction
Brachytherapy is one of the most common modes of treatment of early stage prostate cancer. This
treatment involves the implantation of a predetermined number of radioactive seeds (which is
determined by the treatment type) within the prostate gland. Accurate localisation of the seeds within
the prostate is key to estimating the dose received by the prostate and the surrounding tissue. This is
an integral part of a successful treatment. The current methods for seed localisation suffer from low
accuracy and high cost and cannot be performed in real time.
The BrachyView is a novel online seed localisation detector based on a high-resolution gamma camera
which will assist in the Quality Assurance of Prostate Brachytherapy seed implantation.
In this study, the prototype detector is tested using live Low Dose Rate Brachytherapy seeds within a
Polymethyl Methacrylate (PMMA) phantom, and a soft gel prostate phantom. Optimising the accuracy
of seed localisation is the key objective of the experiments.
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Chapter Two: Literature Review – Prostate Cancer and available
Treatments
Prostate Cancer
In developed countries, the most diagnosed cancer among men is prostate cancer, this
translates to the third most common cause death. It is believed that a positive family history,
age and ethnicity are the strongest risk factors. There are several treatment methods
available for localised and advanced prostate cancers, ranging from active surveillance to
prostectomy to hormonal-deprivation treatments.
In the recent decades, there has been a substantial increase in prostate cancer diagnosis and
this can be linked to better biopsy collection practices, the use of Prostate Specific Antigen
(PSA) and public education.
Prostate tumours are most commonly diagnosed prior to metastasis, this increases chances
of successful treatment as there is of range of treatment modalities available for localised
prostate cancer, such as Prostectomy, radiation therapy or a combination of the two.
Active monitoring is also a very viable solution, as many diagnosed patients die with prostate
cancer and not from it. This is because many cases of moderate to highly differentiated
prostate cancers have a very indolent course, even when left untreated. Treatment methods
of clinically localised prostate cancer depend on tumour characteristics and the patient’s life
expectancy.
Prostate cancer demonstrates little to no symptoms at its early stages. However, as it
progresses, it can lead to urinary discomfort and presence of blood in the urine, Haematuria.
Some of these symptoms are also common to other conditions prevalent in older men and
are non-specific to prostate cancer. As prostate cancer progresses, it can also advance to the
bones resulting in pain. [1]
The prostate is walnut-sized gland, measuring being 3-5 cm between its anterior and posterior
borders. It is responsible for the production of a major constituent of seminal fluid, which is
stored within tubular glands in the prostate. Prostate cancer originates within the cells of the
glands, referred to as adenocarcinoma.
The main two prostate cancer screening methods are the PSA blood test and the Digital Rectal
Examination (DRE). Elevated blood PSA levels can indicate prostate cancer however it is not
a definite diagnosis. Prostatic hyperplasia, a non-malignant condition can also increase PSA
levels in the blood. The PSA blood test is proven to be more sensitive than the DRE; however,
the use of the two tests in conjunction is most effecti ve as they are complementary. The PSA
blood test has definitely increased the number of patients diagnosed with prostate cancer,
this has led to over-diagnosis. This term refers to diagnosis of disease that would not
necessarily affect the patients’ life span or quality of life. Over-diagnosis can cause a negative
financial cost and unnecessary pain and suffering for the diagnosed patients as a result of
treatment. This has increased the detection of early stage prostate cancers; however,
screening has not lead to a decreased regional cancer incidence.
This suggests that, contrary to common belief, screening has not reduced prostate cancer
mortality, only increased the burden of low risk cancers.

6

If a PSA test and a DRE are both indicative of prostate cancer, the protocol examination is
typically a core-needle biopsy of the prostate with either digital or ultrasound used as
guidance. The acceptable standard is 12 biopsy samples (6 per prostate lobes), to be
examined for cancerous cells. If cancer is present, a grade is assigned to the tumour based on
the Gleason tumour grading system. This is done by assigning a score from 1 to 5 to the 2
most common tumour patterns identified, and the addition of these scores determines the
Gleason grade. A higher score suggests more chance of metastasis. [2]

Treatment of Prostate Cancer
There are different modes of treatment available depending on the Gleason grade of th e
tumour, its advancement and size. Following diagnosis, the patient undergoes active
surveillance. This involves further PSA and DRE examinations, and in some cases further
biopsy samples.
Hormonal therapy or Androgen deprivation therapy refers to surgical or chemical castration
in conjunction with Anti-Androgen medication. Another treatment method is Cryoablation
which involves the freezing and thawing the prostate probes using gases under the guidance
of Transrectal Ultrasound (TRUS).
There are different methods of External Bream Radiotherapy (EBRT) available for treatment
of prostate cancer such as Intensity Modulated Radiation Therapy (IMRT), Conformal
Radiation Therapy and Proton Radiation Therapy. High Intensity Focused Ultrasound Therapy
utilises focused ultrasound to raise the temperature of the target cells and destroy them, and
is also an option for prostate cancer patients.
Surgery is also an alternative treatment, ranging from removal of the entire prostate, seminal
vesicles, ampulla of Vas Deferens and in some cases lymph nodes as well. The operation can
be done by open or laparoscopic surgery. [2]
High dosage radiation treatment is generally the standard mode of treatment for patients
diagnosed with intermediate and high risk locally advance d prostate cancer. Hormonal
therapy can be used in conjunction with radiotherapy. This treatment modality has proved to
offer long term control and high overall survival rates. Peeters et al. found that it is possible
to further increase local tumour control by escalating the prescribed dose to 78 Gy or more.
However, they also demonstrated that this treatment method tends to increase late
genitourinary and gastrointestinal toxicity. [3]
IMRT offers the same treatment benefits, while avoiding the some of the adverse effects of
the of radiotherapy. Zelefsky et al. reported that only 2% of patients treated with 81 Gy of
IMRT experienced late grade 2 or higher gastrointestinal toxicity, compared with 14% of
patients treated with the same dose, using three-dimensional radiotherapy. Despite the
benefits of IMRT, this treatment method is not available in every centre. Dose escalation can
also be achieved by adding a boost, typically delivered by a High Dose Rate Brachytherapy
(HDR-BT). Better results and reduced toxicity levels can be achieved using HDR-BT. As this
treatment method has a relatively sharp radiation level fall off, clinicians are able to deliver a
higher biologically-equivalent dose to the tumour, while sparing the rectum and bladder. [4]
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Brachytherapy
Brachytherapy is another type of therapy for localised prostate cancer and is also one of the
most commonly utilised modes of treatment. The Latin word “Brachy” meaning near,
distinguishes Brachytherapy from External Radiation Therapy. The radioactive agents are
inserted directly into the tumour with the aim to maximise the delivered dose to the target
tumour and minimise irradiation to the surrounding organs. Brachytherapy was one of the
first types of radiotherapy used to treat cancer over a century ago. In its early days it was only
used for treatment of superficial and easily accessible tumours. Prostate brachytherapy was
first practiced by Willet Whitmore in the 1970s, however it proved to be a failure, despite its
early success. The disappointing results were due a lack radiographic guidance during the
source implants and no dose delivery plan. Also, due to late diagnosis, the prostate tumours
treated were large and palpable, making them very unlikely to be treated using local
treatments. During the 1980s, megavoltage external beam therapy with its clean,
sophisticated and convenient procedure, coupled with an advanced planning system , became
the more popular treatment method for localised prostate cancer. In the 1990s, prostate
brachytherapy gained popularity among physicians due to several reasons. The first was the
advent of the powerful screening method using PSA, allowing for early detection. The Second
was developments of the TRUS which allowed for a more accurate seed placement method
and patient convenience. There was a widespread disenchantment with the more common
treatment methods such as surgical prostatectomy and External Beam Radiotherapy (EBRT),
in the acceptance of brachytherapy as a standard therapy for prostate cancer. [5]
There are two main types of prostate Brachytherapy:
• High Dose Rate Brachytherapy
The less commonly used method, utilises High Dose Rate (HDR) seeds to deliver fractionated
brachytherapy treatment. A HDR after-loader is used to temporarily place the seeds within
the prostate for a prescribed amount of time. The insertion of these closed-ended needles is
very similar to Permanent implants, and catheters replace the needles. These allow for the
radioactive seeds to be passed through into the prostate. The after-loader is attached to the
catheters via transfer tubes. The radiation source is removed from the patient after the
delivery of the prescribed dose to the tumour.
• Low Dose Rate Brachytherapy
This treatment involves implanting permanent radioactive sources within the prostate using
long hollow needles. During the procedure the patient is always placed in the dorsal lithotomy
position, and the needles are inserted in the prostate using a standard grid. The seeds are
placed within the hollow needles in front of a prod, and as the needles are retracted the seeds
are deposited in the prostate. A typical treatment plan consists of more than 100 seeds. Many
different radiopharmaceuticals and seed designs can be used in Low Dose Rate (LDR)
Brachytherapy. Conventionally, Iodine 125 and Palladium 103 were used in LDR seeds. Also
sources containing Cesium 131 were introduced in 2004. The treatment plan will typically
include the seed type, this will depend on the physician and hospital preference.

Permanent Brachytherapy seeds are cylindrical and measure approximately 4.5mm in length
and have a diameter around 0.8mm. The finer details of seeds’ external shape, internal
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structure and casing material vary with different seed models and manufacturers. The dose
distribution will also be unique to the seed model and isotope used, and is affected by the
internal structure, the thickness and type of cladding material. The of the most important
characteristics of the seeds are the half-life and the energy of the photons emitted, and these
are independent of the physical shape of the seeds. The most commonly used isotope in LDR
Brachytherapy seeds is Iodine 125, with an ideal half-life of around 60 days and average
photon emission energy equal to 27 keV. Another commonly used isotope is Palladium 103,
with a much lower half-life of around 17 days with an average photon emission energy of 23
keV. Cesium 131 has a half-life of 9.7 days and average energy of 29 keV. The half-life of the
isotope determines the speed with which the dose is deposited in the prostate, hence the
importance of this characteristic. Using idone 125, 90% of the dose will be delivered in 197
days compared to 56 days when using seeds containing palladium 103.
TRUS-guided LDR Brachytherapy is the standard method of treatment for low- to moderaterisk locally advanced tumours. This treatment method has disadvantages such as possible
seed migration, permanent radioactive implants in the prostate and its inability to deliver a
high Biologically Equivalent Dose (BED) over a short period of time. HDR Brachytherapy avoids
some of issues related to implanted seeds by utilizing a remote after-loading system (RALS).
This system automatically deploys and retracts a single source of Iridium-192. The radioactive
source is guided through the hollow implant needles, the sources are halted at specific
positions in the patient (the dwell positions) for specific stop times (the dwell times).
Additionally, the source is always contained within the implant needles, thus there is no risk
of seed migration. There is also minimal exposure risk for the clinicians as there is no need for
needle preparation. Inverse dose optimization planning allows for better theoretical dose
distribution.
The HDR Brachytherapy has some significant benefits over LDR Brachytherapy as mentioned,
however it also poses a potential for errors. Intra-operative patient movement, between the
CT and treatment rooms can cause displacement of the implanted HDR catheters. As HDR
Brachytherapy uses very high energy sources (Iradium-192: 380 KeV), a small internal
displacement in seed position, will lead to large dosimetric variations. The high energy
sources of HDR Brachytherapy, when compared to lower energy sources used for LDR
Brachytherapy (Iodine-125 or Paladium-103), do not have a sharp dose fall-off. This can result
in unnecessary and excessive irradiation of the vital surrounding organs. The catheters used
in HDR Brachytherapy can also displace the gold marker fiducials for EBRT, which will lead to
further dosimetric uncertainty. High Dose Rate Brachytherapy requires patient sedation and
catheterization for each fraction delivered, this increases patient hospitalization time, cost
and inconvenience. However, with Low Dose Rate therapy, the permanent radioactive
implants may induce anxiety in the patient and family members, although the radiation the
patient receives is negligible. [6]
As there exists no clinical trials directly comparing the effectiveness of available treatment
methods, treatment choice ultimately depends on patient and physician preference. At
present a number of different treatment methods are commonly used to successfully treat
prostate cancer. Despite the success, each treatment modalities have its unwanted side
effects and complications. The ultimate goal of treatment is to effectively eliminate the
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existing cancerous tumour, thus preventing death or disability from prostate cancer, while
simultaneously limiting treatment-related complications.
EBRT coupled with a single hypo-fractionated boost of 9 Gy HDR-BT is advantageous when
compared to treatment schedules using multi-fractionated boosts. In multiple fractionated
treatment regimes, there exists the risk of inter-fraction movement of marker seeds
which are used for EBRT localisation. However, with the single fraction radiation delivery,
errors due to needle displacement are avoided. Needle displacement can cause geometric
variability, and to verify the needle depth a new CT may be needed. In a single fraction
treatment spinal anaesthesia will only be used once. This will eliminate the trauma caused by
multiple operations and reduces the overall impact on the patient’s life . In terms of patient
comfort, convenience and overall cost, single implant boost is advantageous, as it shortens
hospitalization time, reduces the need for analgesia and minimizes the associated ri sk of deep
venous thrombosis. [2]
Prostatectomy has been the most popular treatment type for prostate cancer in recent years.
However, this procedure remains a challenging urologic surgery, due to the anatomical
position of the prostate gland. The rectum, the bladder and the nerves supplying the penis
are all within a close vicinity of the prostate, therefore an adequate resection aimed at total
cancer control, could lead to loss of functions such as continence and potency. As a result of
accurate screening procedures, the number of diagnosed cases of low -risk prostate cancer
has increased significantly. The early detection means that the diagnosed patients are able to
live for longer with prostate cancer and therefore places added emphasis on post-treatment
quality of life. [7]

Radiobiology
With respect to radiobiology, the number of cancer cells destructed is proportional to the
radiation dose delivered to the patient, unfortunately the same is true for the healthy
surrounding tissue. The α/β ratio is an estimate of how radiation affects the various parts of
the body, and is an excellent measure for comparing treatment plans concerning dose and
number of fractions. The term, α, refers to the cells that will dies after a single hit of radiation,
defining the initial slopr of the radiation dose-response curve. Conversely the term β
describes the latter part of this slope and is related to the cells in the tumour that require
more than one hit of radiation due to the ability to repopulate and repair. The α/β ratio
estimates how sensitive cells are to the radiation, thus determining the effectiveness of the
treatment. A high ratio suggests that target cells are rapidly multiplying, thus implying that
low-dose radiation delivered over many fractions is more effective at destroying the cells.
Conversely a low α/β ratio is characteristic of slowly proliferating cells, meaning high-dose
radiation delivered in a few fractions will be more successful at cell destruction. The α/β ratio
is used in the calculation of the BED.
𝑑
𝐵𝐸𝐷 = 𝑛𝑑 [1 + α ]
⁄β
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Where, n refers to the number of fractions and d is the dose delivered during each fraction.
A low α/β ratio for the prostate tumour has been hypothesized (~ 1.5 Gy) suggesting that its
cancerous cells are more susceptible to higher doses delivered in fewer fractions. Higher dose
per fraction delivered to tumours with a lower α/β ratio than their surrounding healthy tissue,
will result in a higher BED for the tumour than its surrounding healthy tissue, thi s would then
increase the therapeutic ratio. [8]

Comparison of treatment Methods
Surgery and radiation therapy, whether it be in the form of EBRT or Permanent Prostate
Brachytherapy (PPB) tend to have similar outcomes when treating patients with an earl y stage
diagnosed disease. As expected, younger patients are equally concerned with the cancer
survival outcome and quality of life after treatment, when choosing treatment type. As a
result of this, post-treatment quality of life has gained increasing significance over the recent
years.
The three main aspects concerning post-treatment quality of life are sexual, urinary and bowl
function. Voulgaris et al. reports that, patients with PPB have significantly better posttreatment sexual function than those with high-dose EBRT or radical prostectomy. In addition,
they approximate that 84% of the potent men treated at their centre, retain potency after
treatment. In terms of urinary system dysfunction, the results are not as clear.
Following Brachytherapy, incontinence is very rare as suggested by the results gathered at
the Guilford Cancer Centre. [8]
Bladder dysfunction is more common after brachytherapy treatment, and urinary
incontinence is more prevalent post prostectomy. Urinary and sexual dysfunction are
generally more common post radical surgery when compared to radiation treatment (EBRT,
PPB or a combination of the two). However, issues concerning bowl function are more
consistently reported by men who undergo radiotherapy than surgery. It is worthy to mention
that most statistics concerning post-treatment quality of life, do not distinguish between
Brachytherapy coupled with EBRT from mono-therapeutic Brachytherapy.
A quantitative evaluation of quality of life is very difficult to obtain, due to the significant bias
placed on the matter by different individuals, also clinical and statistical data need to be
considered. Nevertheless, if the patient prioritises potency and continence regarding quality
of life post procedure Iodine 125 PPB implant may be the optimal form of definitive
treatment. [9]

Brachytherapy Planning Procedures
Depending on the institution, the brachytherapy implantation procedure differs in treatment
pre-planning, intra-operative planning and equipment. There are four main methods of
implementation in regard to treatment planning:
•

Preplanning: The treatment plan is prepared days or even weeks prior to the
procedure using ultrasound and other imaging techniques (such as CT or MR imaging).
The implantation is performed according to the treatment plan. It is crucial that the
patient’s anatomy is duplicated exactly from the volume study. Historically, this
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planning system has the most amount of clinical experience and can produce great
outcomes if performed correctly.
•

Intra-operative: The ultrasound images and the volume study are used to construct
treatment plan in the operating room. This method offers the great advantage of a
more accurate patient geometry and volumetric study. However, some clinicians
argue that this planning technique is flawed, as the pressures of preparing a complex
treatment plan, while the patient is under anaesthetic and a large group of staff
member waiting in the operating room, encourages mistakes, and discourages a
thorough review of the treatment plan with an extended discussion of the treatment
plan and consideration of the alternatives.
• Interactive: Using a pre-prepared as well as an intra-operative treatment plan, the
operation is undertaken guided by ultrasound images. This technique offers some
flexibility, as the treatment plan is altered according to the positioning of needles and
the patient’s anatomy deformation.
• Dynamic dose calculation is often adopted in this technique: Using ultrasound images
of the prostate and the effective needle positions, the dose distribution is updated in
real time. This allows for alteration of seed positions based on real time dose
distribution and for a much more flexible procedure, and allows the physician to alter
the plan to accommodate for under-dosed and over-dosed areas. This technique can
increase time in the operating room, as the dose distribution has to be acquired after
implanting the needles. Quality Assurance (QA) methods which accurately localise the
seeds within the prostate in real time, from which the dose distributions can be
recalculated are strongly desirable.

Quality Assurance and planning for brachytherapy
Quality Assurance for LDR brachytherapy is typically provided in real time, using a specialised
ultrasound unit. The TRUS probe can acquire images axially or sagittally using two sets of
separate ultrasound crystals. Both sets of images are helpful, in providing information about
the positions of the needles in reference to anatomical features, i.e. prostate base and apex,
rectum wall and urethra. The position of the TRUS probe is accurately adjusted by turning a
knob connected to a “stepper” unit, which holds the probe securely in place. Each click of the
stepper moves the TRUS probe crystals and the ultrasound image of 5 mm (standard clinical
setting). The needle template is also mounted on the stepper unit, but it is fixed in respect to
the patient and the TRUS longitudinal axis (see Figure 2.1). The standard template is a 13 by
13 grid of holes sized for needles. The rows are labelled f rom 0 to 6.5 in increments of 0.5
(5mm) from bottom to the top. The columns are designated by letters A, a, B, b etc. The grid
pattern is also overlaid on the patient ultrasound image which is then co-registered with the
grid on the stepper allowing for accurate insertion of the needles. [10]
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Fig.2.1: image of a TRUS probe setup on a plastic phantom; the grid template and the stepper unit are clearly visible. Taken
by the author at the St. George Hospital.

To ensure that the pubic bone does not interfere with the needles, the patient is always
situated in the dorsal lithotomy position. This position allows better access to the prostate
and is easily reproducible when switching from the volume study to the implant operation.
Prior to the operation it is essential to match the patient’s anatomy from the volume study,
to avoid discrepancies in the seeds’ positions from the treatment plan.
Implant quality assurance in PPB is determined post-implant and can range from hours to
weeks after the procedure. Computed Tomography (CT) imaging is recommended modality
for post implant seed localisation. Variations in CT-obtained prostate volume can result in
incorrect Dose Volume Statistics and Quality Assurance of the implantation. An excellent
alternative to CT-based post implant examination is the TRUS, which is reproducible and is
also used for intraoperative implantation guidance in PPB. There are some advantages and
disadvantages using TRUS as a post implant dosimetry method. Automated seed sorting using
CT is effective at seed localisation but is generally regarded as less effective to TRUS in
determination of the prostate outline and volume determination. Also, CT seems to have a
higher inter-observer variability in prostate segmentation than TRUS. This variability can
result in differences in clinically relevant dosimetry parameters.
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A dosimetry system based on TRUS is the more attractive to physicians as it is fast and low
cost and is also more accurate in determining the prostate volume than CT-based systems.
However, TRUS has a limited ability to localise seeds within the prostate, this is due to the
reduced ultrasound back-scatter from standard seeds. There are ultrasound opaque seeds
available on the market which are designed to be visible on a standard ul trasound dataset but
they are expensive and rarely used clinically.
Transrectal Ultrasound is an excellent imaging tool used for the initial planning dosimetry for
permanent prostate Brachytherapy. For post-implant dosimetry CT is most commonly used,
for its superior imaging abilities especially for resolving high density seeds. Post-implant
dosimetry is subject to a number uncertainties and difficulties, as the implantation can result
in swelling and distortion of the prostate. Despite these challenges, an immediate (day 0)
post-implant check can be very beneficial, as it presents the opportunity to intervene and re implant in case of a large deviance from the treatment plan. A typical post-implant dosimetry
is undertaken 4-6 weeks after the procedure, which allows operative effects to subside. The
most significant uncertainties in post-operative dose calculations are caused by interobserver variability. This is due to individual variability in contouring of the prostate volume.
[11]
Due to the inherent but differing disadvantages of these methods, fusing the two modalities
could potentially capitalize on the strengths of each modality. This could result in a more
accurate and reproducible post-implant dosimetry procedure. This image fusion in real time
will allow for immediate dosimetry, which will give the physicians the chance to correct any
suboptimal implant in the operating room. [12]
In the study conducted by Daanen et al, the MR is brought to the operating room and
combined with a TRUS probe, using a TRUS/MRI fusion technique. This does not require the
presence of both the patient and the implantation team in the MRI room while assisting the
clinician in treatment planning. This project reviews a rigid and an elastic co-registration of
MRI and TRUS images. A pre-operative MRI of the prostate is acquired, three orthogonal T2
TSE volumes are obtained via an endo-rectal coil and the prostate contours are segmented
jointly on the three volumes. Conventional axial TRUS slices are collected to produce a threedimensional prostate model, intra-operatively. Ultimately the objective of the registration is
a perfect superimposition of the prostate volumes. This process can also determine prostate
movement and deformation pre- and intra-operatively. The co-registration is initialized by
superimposing the centres of gravity of the two prostate volumes. This initial rough
estimation can determine the rotation and translation parameters between datasets, and
highlights any local deformations or distortions.
In this project, the initialization method uses an adaptive, hierarchical and regularized freeform deformation of the one volume to the other coordinate system. The optimization stage
is based on the Levenberg-Marquadt minimization procedure. This produces a threedimensional function, transforming any US data point to the corresponding MRI point. [13]
In a study conducted by Shaikh et al. the treatment plan is produced using a MRI-generated,
contoured volume. The tumour contouring is done by an experienced phys ician and is
reviewed by at least another experienced practitioner. The treatment is monitored by real
time transrectal ultrasound. Rigid cystoscopy (the examination of the lining of the bladder
and urethra) is performed by the oncologist to ensure the absence of needles and seeds in

14

the urethra or the bladder. Approximately four hours post-implant, the catheters are
removed and the patient undergoes a post implant CT and MRI, to determine baseline
dosimetry, this will be regarded as day-0. The patient will return for a day-21 dosimetric
examination, via the same imaging techniques.
In this study the primary dose constraint was >145 Gy prescribed to 90% of the prostate
volume (D90 > 145 Gy); a secondary constraint was that the volume of the prostate wuold
receive >90% of the prescription dose (V100 >90%). Image fusion of CT and MRI are used for
post implant dosimetry for day-0 and day-21, the contouring of the prostate is performed by
the same physician to minimize variability. Comparison of the two post-implant dosimetric
examinations allows physicians to check for seed position stability and quality assurance of
the entire procedure, ensuring the prescribed dose is delivered to the tumour volume. As
under-dosing the target area can lead to failed treatment. [14]
Another study under taken by Takiar et al. investigates the advantages of using fused CT/MRI
scans in conjunction with sector analysis for post-implant dosimetric analysis.
Takiar el al. uses sector analysis in place of dose-volume histograms to verify post-implant
dosimetry. Sector analysis is a useful analytical tool that allows evaluation of the dose
distribution to individual portions of the prostate in addition to the entire gland. This
approach in post-implant dosimetry of the prostate, offers a significant advantage over
standard dose-volume histogram analysis. As most patients treated with brachytherapy, are
diagnosed with locally confined disease rather than involvement of the entire organ.
Recognizing routinely under-dosed and over-dosed portion of the prostate will allow for
improvement of treatment planning and delivery. The standardization of the sector analysis
allows for comparison between patients and institutions, and also allows for findings to be
evaluated in terms of outcomes and toxicity. It is admitted that the most significant limitation
of sector analysis is that the quality of the output depends on the accuracy of the contouring.
It is difficult to delineate the prostate apex and base on CT images, therefore many studies
have suggested the fusion of CT and MR images as means of overcoming this limitation.
In this study, all patients selected were implanted with Palladium-103 stranded seeds
according to the treatment plan designed under TRUS guidance. As a means of QA in the
operating room, an anterior–posterior fluoroscopic image was acquired immediately after
source implantation to grossly confirm placement as planned. CT images were then obtained
using a 2.5 mm slice width to verify the quality of the implants. Another CT was performed
on day 30; these images were used for the CT-based post-implant dosimetry to account for
any prostatic edema due to the procedure.
All patients also underwent MR scans with 5 mm width on day 30. These images were then
manually co-registered with the day 30 CT images using a point-based fusion. This method
aligns selected seeds at the base and apex on the CT scan with the seed or needle -path voids
on the MR image. Bony landmarks were not used to co-register the images due to the
possibility of prostate movement as result of patient position and extent of bladder and
rectum filling.
This clinical study has severe limitations, one of which was the follow up time. The mean
follow-up time was 24 months; this is short by any means in comparison to othe r studies of
similar objectives. Another potential factor for problems is the quality of co-registration of
the two images. Imprecise fusion could negatively affect sector analysis and influence
consequent interpretations.
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Takiar el al conclude that their findings demonstrate the feasibility of CT/MRI- based postimplant dosimetry using sector analysis. This approach helped the team to accurately
delineate the anatomical margins of the organ using the MR images. While sector analysis
proved useful when comparing patients’ treatment plans and outcomes. [15]

From the reviewed studies, it can be concluded that, there are no available techniques for
intra-operative quality assurance that is able to reconstruct the position of the seeds in Low
Dose Brachytherapy or track the trajectory of the seeds in High Dose treatment. The existing
methods involve the use of an external source of radiation for imaging, which increases the
total dose received by the patient, as well as treatment time and cost. The availability of real
time tracking also allows the practitioners to alter the treatment plan to avoid under/over
dosing critical target areas, if necessary. No feasible real -time techniques which are cost
effective and do not use external radiation sources, have been proposed.
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Chapter Three: BrachyView Concept
Centre of Medical Radiation Physics (CMRP) at University of Wollongong (Australia) proposes
the BrachyView Project for both HDR and LDR treatments. This study will focus on th e proof
of concept BrachyView for Low Dose Rate Brachytherapy, using a large number of seeds in a
plastic phantom and TRUS co-registration in a deformable gel phantom.

This research project proposes a novel in-body imaging technique using a high spatial
resolution gamma camera embedded in a TRUS probe for real -time in vivo seed identification
concurrent with a prostate ultrasound dataset. This tracking device consists of a planar
pixelated silicon detector encased in a multi-pinhole tungsten collimator. The detector is
aimed to have an accuracy of 1.5 mm with a sub-second temporal resolution.
The BrachyView probe consists of three side-by-side Medipix2 detectors. These detectors
allow for a total imaging area of 14 x 42𝑚𝑚2 (256 × 768 pixels with individual pixel size of 55
× 55μ𝑚 2 ), and were manufactured in collaboration with the Institute of Experimental and
Applied Physics of Czech Technical University of Prague. The images of the radioactive seeds
are acquired through the pinholes above the detector surface. In contrast to most pinhole
systems, BrachyView works in demagnification mode (magnification factor of less than 1)
which is made possible by the superior spatial resolution of the Medipix2 detectors. In
Medipix2, each pixel has its own independent pre-amplification channel, coupled with two
discriminator levels. This allows for the detection of each individual photon that strikes a
pixel, where it will deposit its energy, and if this is higher than the energy threshold, increment
the counter by one count. The count is then digitally readout by a USB interface with a refresh
rate of a few hundred Hertz.

The presence of the tungsten collimator represents a potential problem for the rectum wall
which could be affected by the dose enhancement generated by the backscattered radiation
from the collimator.
A study by Han et al. set out to investigate the effects of such backscatter radiation. The
experiments are accompanied by Monte Carlo simulations for confirmation purposes.
All experiments and simulations performed are aimed to measure Backscatter Dose
Correction Factor, (BSDF), which is defined “as the ratio of the dose measured within a
homogenous tissue equivalent volume with and without the presence of a hi gh electron
density region” [14] (i.e. tungsten collimator).
The simulations show that the backscattered electrons resulted in significant dose
enhancement within very close proximity of the collimator. This is translated from a high
value of BSDF, however this ratio rapidly diminished to unity (i.e. no measurable backscatter
resulting in dose increase) at a distance less than 1 mm from the high Z material. The
experimental results closely resembled the simulations for a planar tungsten collimator.
The team at CMRP then concluded, based on the measurements from the MOSkin and the
results from the Monte Carlo simulations, that dose enhancement by backscattered electrons
is expected to be negligible beyond 1mm from the collimator surface. The researchers als o
mention that the final probe will be encased in a protective 1 mm thick medical -grade
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sterilisable tissue equivalent plastic shell, which will absorb the majority of the backscatter
dose. [17]

As previously mentioned, following the treatment planned is crucial to the effectiveness of
the procedure, as this ensures the tumour and surrounding tissue receive the prescribed
dose. Therefore, localisation is vital to confirm that the treatment planned is followed as
closely as possible. Intra-operative dynamic treatment planning allows for compensation of
misplaced seeds, thus covering the cold spot they introduce. Intra-operative monitoring is
imperative to maximize the benefits of prostate brachytherapy yet keeping the dose
constraints to critical organs in check.
In a feasibility study of BrachyView for LDR brachytherapy, Petasecca et al. aim to reconstruct
the spatial coordinates of four strategically placed seeds within a PMMA block mimicking the
clinical brachytherapy grid positions. The placement of the four seeds, will effectively test out
the gamma camera in the following ways:
•
•
•

Evaluate the effect of the source to collimator distance (SCD)
Evaluate the projected image quality of the two seeds positioned simultaneously, (one
close to the camera and hence bright, and the other far producing a weaker signal)
Verify the extension of the field of view (FOV) with implanted seed in the periphery.

The two most important parameters characterized in this work are the transverse and
longitudinal resolution of the camera. The team at CMRP found that the transverse spatial
resolution is in the submillimeter range, at low SCD. However, at a SCD of 60mm the
transverse spatial resolution is 4mm, which is not acceptable for resolving brachytherapy
seeds. A solution proposed, is to use a smaller pinhole with a diameter of 150-180 μm. A
pinhole of this size will allow sufficient counts to be received by the detector while sparing
the transverse spatial resolution at higher SCD. In contrast the longitudinal resolution is much
more robust, and was found to only be affected by the focal length (∝1/f^20). This physical
feature of the system must be very accurately determined.
The sensitivity of the spatial resolution of the camera highlights the significance of accurate
manufacturing of the pinhole.
The focus of this project is the possibility to co-register the 3D coordinates obtained by the
pinhole camera with the anatomical image of the prostate obtained by the TRUS prob. Due
to its small size, this gamma camera can be integrated with a TRUS probe with dimensions of
22-24mm, which is acceptable for patient use. The integration of the two systems in one
probe seems challenging from an engineering perspective, however the co-registration of the
images will be relatively simple. The instrument will have an ultrasound transceiver and the
triple chip Medipix2 detector along with its pinhole collimator on opposite halves of the
cylindrical probe. Sharing the same central plane will allow for an easy co -registration
algorithm, as they would also share a common spatial coordinate frame. The cylindrical shell
will be ultrasound and radiation transparent, and will be in contact with the rectal wall. The
inside apparatus can be rotated on a central axis, allowing easy transition between the two
imaging systems. [18]
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The BrachyView rectal probe design is based on a multi-pinhole lead collimator and three side
by side Medipix2 detectors. Each element of the probe is presented below, beginning with a
description of Medipix, a study for the optimisation of the tungsten collimator and the
description of the technique used to reconstruct the position of the gamma source in 3D using
triangulation. Figure 3.1 is a schematic representation of the BrachyView probe concept.

Fig.3.1: BrachyView probe concept and schematic representation

Semiconductor radiation detectors
Semiconductor pixel detectors are a particularly important class of radiation detectors,
mostly due to their broad spectrum of applications. Although they were originally designed
for high energy physics, they slowly found their way into different fields, due to their
reliability, excellent resolution and cheap production cost.
Semiconductor radiation detector consist of arrays of semiconducting diodes with their
electrodes depleted with a reverse bias. As ionizing particles strike the depleted volume of
the detector, a charge is created which drifts towards the electrodes via the electric field . The
collected carrier current is often integrated by the read-out electronic which is responsible
for signal amplification, discrimination and analogue to digital conversion (ADC). Pixelated
detector with individual electronic chains capable of signal processing for each pixel are
referred to as Pixelated Hybrid Semiconductor Detectors. The hybrid device is composed of
two chips, the sensor chip which is a semiconductor diode where the charge is deposited, and
the readout chip which contains the electronics for all pixels and is bump-bonded to the first
chip. An example of this type of detector is the Medipix2. The monolithic devices are
comprised of one chip, which acts as a sensor and performs a basic electronic readout through
a source follower or a current amplifier. This type of device is referred to as DEPFET Macropixel detector and is developed in MPI Semiconductor lab in Munich, Germany.
Charge sharing is a common problem which affects pixel detectors, as the charge cloud
created by the ionizing particles striking the surface of the detector are able to expand and
travel through the face of the detector during the charge collection process. This originates
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mainly from electrostatic repulsion and charge diffusion and poses difficulties as the charge
can be collected by several adjacent pixels forming a cluster.
In detectors with a small pixel size and/or thick sensor, the original charge is almost never
completely collected by a single pixel. The collected charge from the ionizing radiation is
compared to a set threshold level and if lower, the charge is not registered and thus the
charge is lost. Due to charge sharing, the charge registered over a number of pixels will usually
be lower than the set threshold, which results in loss of the signal, and deteriorates the energy
resolution. [19]

Medipix2
The Medipix collaboration developed a single photon counting pixel detector readout chip
using a 0.25μm CMOS process. In high energy physics, hybrid pixel detectors are most
desirable as they provide practically “noise free images” of particle collisions. These detectors
typically work by using a preamplifier, which amplifies the charge deposi ted in a sensor,
producing a fast-shaped pulse. This is compared to a set threshold, to then increment the
counter. This type of detector is capable of imaging with practically no noise, which is the
main interest in such devices.
The Medipix2 detector has a square surface which consists of a matrix of 256 x 256 square
pixels each measuring 55μm on the side. The deposited charge, caused by the ionizing
radiation, enters the pixel through the aluminium bump bonding pad. The charge is then,
integrated on the feedback capacitor of the pre-amplifier. There are two set thresholds, and
they can be adjusted within each pixel, this is to avoid pixel-to-pixel threshold variation. The
amplified voltage is compared to the set thresholds and if it falls within its range, a single
pulse is generated at the output of the double discriminator logic. An external shutter is
applied to the chip, when this shutter is active the pulses from the double discriminator logic
are then connected the clock of the pseudo-random counter within the pixel, resulting in each
pulse incrementing the counter by one.
The standard chip is comprised of a single chip readout and a single sensor made of 300μm
thick high resistivity Silicon which are connected via bump-bonding. The single chips can be
assembled into different configurations allowing for larger detection areas serving di fferent
purposes. [20]

Timepix is the replacement detector to the Medipix2. Timepix has the same physical
dimensions and features as the Medipix2 detector; with the added ability of each pixel to
operate in three different mode: Medipix mode (counts the number of striking particles),
Timepix mode (counter works as a timer and measure time of interaction) and Time -overThreshold (TOT) mode, which allows for direct energy measurement in each pixel. Jakubek et
al. studies the effects of charge sharing on the hybrid silicon pixel detector.
The charged collected within each individual pixel can be measure when the Timep ix is
operated in the TOT mode. The detector consists of 65536 individual pixels each with their
corresponding and independent channels, with a non-uniform energy response. This obviates
the need to calibrate each pixel. The calibration procedure uses pixel clusters of different
sizes, neglecting the charge lost due to charge sharing to adjacent pixels. A detected particle
creates a cluster of pixels, with its total energy equating to the sum of the calibrated
responses of pixels in the cluster, plus the charge lost due to leakage. The lost charge will
cause a distortion between different sized clusters, which was recorded experimentally. The
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same process was investigated using simulations and the results agreed well with the
experimental data.
There are three main factors that play a role in the charge sharing effect, the speed of the
charge collection which is determined by the bias voltage, the deposited energy and the
depth of particle interaction. A simple experiment was designed to study the influence of the
interaction depth on charge sharing. A tilted detector was illuminated by X-ray photons
through a slit (mimicking a point source), this set up allows for determination of cluster size
on the depth of interaction. By analysing each recorded cluster separately, it was found that
the average cluster size has a quadratic dependence on the depth of interaction. This result
implies a linear relationship between average cluster radius and interaction depth. [ 21]

Medipix2 used in Radiotherapy
The development of cancer treatment methodologies based on hadron beams, such as ions
and protons, is mainly due to their advantageous depth-dose distribution and the excellent
radiobiological effective they offer. In Catania, Italy, the Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud has been operating using a superconducting cyclotron which
generates proton beams with a maximum energy of 62 MeV. For clinical use the beam passes
through a series of modulators, range shifters and collimators. Quality assurance of the beam
specifications is an integral procedure prior to any treatment period. The team at this centre
have set out to develop a detection system based on the Medipix2.
The Medipix2 detection system was used as a single proton counting device, monitored by a
control detection system based on a YAP:Ce scintillating crystal. This crystal was chosen due
to its superior properties such as medium-high density, high light yield and fast response. The
measurements taken by Medipix2 were accurately matched by the control system, which
demonstrates its capability as a single proton counting device. Due to its fast acquisition time,
this system can be proposed as a routine beam detection system. [22]
The Medipix2 offers many features that may be favourable for X-ray dosimetry. This detector
allows noiseless photon counting which presents the opportunity to monitor low energy
photons as low as 3.5 keV. The small pixel size allows for processing of high dose rates, and
due to the large number of pixels, dosimetry at low does is also possible. Michel et al. has
developed a system based on photon counting pixel detectors, such as the Medipix2, th at can
determine personal dose equivalents from the number of counts in energy deposition
intervals.
The Medipix2 is capable of detecting single photons with energies as low as 3-4 keV. This
allows for the possibility of detecting a small number of photons with very low energies. It
has been demonstrated that the surface dose delivered by very low energy photons increases
with decreasing photon energy. An active personal dosimeter can examine the leakage
radiation and therefore reduce the risk to the practitioners.
The aim of this study was to demonstrate the advantages of using personal dosimeters based
on photon counting pixel detectors such as the Medipix2 when measuring personal dose
equivalents for photon beams with energies below 150 keV. Although these detectors suffer
from charge sharing which introduce defects in such dosimeters, they still prove to be capable
of personal dosimetry. Due to the nature of development of Medipix2 being medical imaging,
it does not have a problem detecting pulsed beams; this is an advantage of this system when
compared to active personal dosimeters based on other detectors.
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The Medipix2 has power consumption in order of several hundred mW, depending on
counting and readout activity. Therefore, it is impossible to have continuous operations for
extended periods of time. By using low power front-end in the pixel electronics, it will be
possible for the photon detector to be used for several days without recharging.
A major problem with a Medipix2-based personal dosimeter, is the angle of incidence of the
radiation. Only photon beams perpendicular to the detector will deposit their entire energy
with in the sensor layer. This is due to the self-attenuation of the photons within the upper
Silicon layer.
A personal dosimeter based on the Medpix2 has a number of benefits, such its small lower
threshold of its energy range, its large range concerning dose rate and its very high statistical
accuracy at low dose levels. [23]
Another application of Medipix in radiotherapy has been explored by CMRP for eye plaque
brachytherapy. Radiotherapy is the most common type of treatment for posterior unveal
melanoma, and of the available radiotherapy treatment methods, the most preferred is
brachytherapy. This is mostly due to the high cost and lack of widespread accessibility of its
rival treatment type, proton therapy.
Eye brachytherapy typically uses I-125 or Pd-103 seeds, encapsulated within a Ru-106 for
uniformly coated plaques. The TG-43 is the governing protocol for all brachytherapy
calculations, it assumes an infinite body of water and does not account for an eye plaque.
There exists a limited range of quality assurance techniques for customized plaques. By
considering factors affecting the complexity of the treatment, for instance, the tumour size,
shape and location, the surrounding vital tissue can be considered and spared.
A 3D dosimetry of the eye plaque will provide an improved QA for the eye brachytherapy
treatment. Weaver et al. suggests the incorporation of a pixelated, silicon detector, the
Medipix2, for the development of such a system. The importance of dose verification of the
eye plaque is highlighted by the dose variability of the dose and misplacement of the seeds
within the plaque. The study conducted the CMRP at University of Wollongong aims to
improve the existing clinical QA for brachytherapy treatment through the development of a
treatment plan evaluation system.
The effects of backscatter from the material positioned adjacent to the detector were studied
to allow for optimal design of a QA system. Another focus of this project was to compare the
event counting mode of the Medipix2 to the Time over Threshold mode on the Timepix for I 125 dosimetry. The total charge deposited in the sensor layer can be determine d by running
the Timpix in TOT mode.
Using the excellent imaging properties of the Medipix2 detector, Weaver et al. could
determine the effects of backscatter to the dose received by the detector. This information is
crucial for the improvement of the QA systems in place. They also determined that the TOT
and count mode were significantly similar, and concluded that a dosimetry system based on
the Medipix2 in event counting mode presents a cheaper and simpler alternative. [ 24]
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Pinhole design and optimisation
In a comprehensive study of the pinhole size and shape at the CMRP s at the University of
Wollongong, Alnaghy et al. set out to investigate pinhole geometry, more specifically, singlecone verses double cone design. An analytical model is further developed for a single cone
pinhole, and its findings are validated using Monte Carlo simulations. This project was aimed
at determining the optimal pinhole design to be used in the HDR BrachyView Project.
The most important parameters of a pinhole photon detection system are spatial resolution
and sensitivity, which ideally should be as high as possible. In a pinhole system, the spatial
resolution is defined in terms of the width of the Pinhole Response Function (PRF) exceeding
a fraction (k) of its maximum value. The PRF is the 2D spatial distribution of the photons
emitted by a point source and passed through the pinhole to reach the detector. The total
sensitivity of the pinhole is determined by the sum of the geometric sensitivity which is the
fraction of photons passing through the pinhole the pinhole aperture, and the penetrative
sensitivity, which represents the fraction of photons attenuating through the collimator
medium.
The analytical model was designed for a single cone geometry and compared to an existing
equivalent model for a double cone geometry. The Monte Carlo simulations of a realistic point
source model, agree with the theoretical values of the Full Width Half Maximum (FWHM) of
the PRFs. The Penetrative Sensitivity of the double-cone pinhole system was shown to
decrease more rapidly than the single cone system. This is particularly true for large horizontal
displacement of the point source.
In the HDR BrachyView, the projections of centre of mass of the seeds is the most vital
information acquired through the pinhole, its accuracy is very important to estimate the
projection the centre of the source. The centre of mass for the true projected seeds is proved
to be in good agreement with the Monte Carlo simulations for both pinhole designs for seeds
contained in the full field of view. However, a much greater difference was observed for seeds
nearing the edge of the field of view using the single cone aperture.
The double cone pinhole design was shown to have better sensitivity, spatial re solution and
more capable of estimating projected centre of seeds, than its rival aperture design. The team
at University of Wollongong appropriately concluded that the double cone pinhole was more
suitable for the purposes of the HDR BrachyView probe. [25]
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Chapter Four: 20 Seeds Experiment
The present chapter describes the main work performed in this thesis and published in the
paper listed below. The candidate was the main person responsible for experimental setup,
measurements during the experiment, reconstruction of the seeds and the analysis of the
results. He also contributed to the writing some parts of the paper and producing most the
images and tables present.
Alnaghy, S., Loo, K., Cutajar, D., Jalayer, M., Tenconi, C., Favoino, M., Rietti, R., Tartaglia, M.,
Carriero, F., Safavi-Naeini, M., Bucci, J., Jakubek, J., Pospisil, S., Zaider, M., Lerch, M.,
Rosenfeld, A. and Petasecca, M. (2016). BrachyView: multiple seed position reconstruction
and comparison with CT post-implant dosimetry. Journal of Instrumentation, 11(05),
pp.P05002-P05002.

Materials and Methods
The original design of the BrachyView probe, is based on a multi -chip version of the Timepix
detector, consisting of four separate sensors, aligned horizontally. The “edgeless ” technology
featured in the multi-chip, allows for maximum detection space, with a minimal dead layer of
25μm. Due to prolonged unavailability of a functioning multi -chip setup, for the purposes of
this experiment a single chip Timepix detector was coupled with a single pinhole lead
collimator. To mimic the multi-chip configuration, the single Timepix chip is translated in
15mm increments using a high precision stepper motor.
The collimator utilised in this experiment is constructed by hand from a flat patch of lead of
1.2mm thickness. It features a single cone-shaped pinhole with major diameter of 800μm and
minor diameter of 200μm. An analytical proof of pinhole optimization was formerly done by
Alnaghy et al. the shape and the size of the pinhole for this experiment was guided via the
previous work done and experimental work using active I-125 seeds. [25]
The phantom used in this experiment was constructed at University of Wollongong, from
Polymethyl methacrylate (PMMA). This material was chosen for its similar density to the body
tissue and it clear structure. The phantom measures 60x60x60mm3 and features a matrix of
holes drilled through its length. The template used in this experiment is the CIVCO™ LDR
Sterile 17GA Grid, for 1.3mm diameter open ended needles. In a clinical scenario this
template provides a series of precisely placed needle guide channels, which enables accurate
placement and insertion of the needles, in relation to the ultrasound imaging probe. In this
study it was used for correct placement of the loaded needles into the phantom in relation to
a clinical layout.
For the purposes of this experiment, twenty loose I-125 seeds (model 6711 Oncura) were
acquired. I-125 Seeds feature a gold radiopaque marker in the centre which is enclosed in a
thin layer of Aluminium and coated with a thin layer of Copper. The entire seed is
encapsulated in a Titanium shell and measures approximately 4mm in length and 1mm in
diameter. The activity of batch was examined using a well-type ionization chamber at the St.
George hospital in Sydney pre-implantation. According to Australian College of Physical
Scientists and Engineers in Medicine (ACPSEM) standards, devices used for clinical quality
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checks need to be calibrated periodically, in intervals no longer than 2 years. For clinical
purposes the activity of 10% of the batch or 10 seeds are measured, however to ensure the
activity of all the seeds was in good agreement, the whole batch was tested. Each seed was
placed in the insert of the chamber and measured twice, for 60 seconds, in each orientation,
to ensure uniformity of the radioactive component within the source. Lead shielding was used
to ensure radiation protection as the seeds were active.
The ACPSEM recommends that individual source activity verified by a well chamber needs to
be within 3% for loose seeds. Considering this requirement, an average Air KERMA strength
of 0.455 𝜇𝐺𝑦 𝑚2 ℎ −1 was determined for the entire set of seeds. The treatment plan was
devised by an experienced oncologist, and is based on a standard clinical scheme. As evident
in Figure 4.1, the hypothetical location of the intra-prostatic urethra is not implanted. The
needles were inserted in positions, B3, C2, c3.5, D2, E2 and F3. Table 1 demonstrates the
loaded needle positions with the activity of the corresponding seeds. In a clinical setting the
implantation process starts in the top left corner of the plan and progresses to the bottom
right, this was the method of implantation employed with the following order: c3.5, d3.5, B3,
F3, C2, D2, E2. Figure 4.1 displays the PMMA phantom with the inserted needles highlighted.

Fig. 4.1: Schematic showing 60x60x60𝑚𝑚3 PMMA phantom with the positions of the 20 active seeds marked grey. The
number of seeds within each needle is indicated. The same coordinate system is used for the identification of the seeds.

The images were acquired using a single Timepix detector, and were monitored during the
implantation process in real-time. This demonstrated the capability of the system to identify
individual seeds as they were implanted within the phantom. In a clinical scenario, there is a
delay of approximately one minute between each needle implant, which reflects the abilities
of an experienced oncologist. This time delay allows for the acquisition of the photons
emitted by a set of seeds in each needle, via the gamma camera.
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Fig. 4.2: Photograph of experimental setup taken from above, displaying the PMMA phantom with drilled holes and stepper
motor with direction of translation.

The experiment took place in a CT scan room at the Cancer Care Centre within Sydney’s St.
George Hospital. A full CT scan was acquired using the medical CT scanner in the room,
Siemens SEMATOM® Emotion, as the experiment was set up on the CT bed, the apparatus
was not moved, eliminating motion errors in the results. To allow for a more accurate 3D
reconstruction, a slice width of 0.8mm was used for the CT scan, in comparison a routine
clinical CT 2mm thick slices. To emphasise “bone density”, the images were post-processed,
a CT number window between 400 – 1200 was used to highlight the shape and position of
the implanted seeds. This also aids to reduce the effects of the artefacts introduced to images
due to the material with high-density used in the experimental setup such as the optical
bench pillars. Figure 4.2 and Figure 4.3 demonstrate the experimental setup in the CT
operation room.
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Fig. 4.3: The experimental set-up consists of the detector, the phantom and the high-precision stepper motor, fixed on an
Aluminium optical Bench. The Experiment was performed at a CT suit e room at the Caner Care Centre at the St. George
Hospital

After each needle was implanted, the pinhole camera acquired three projections of the
phantom in 15mm intervals, and a full CT was taken. The CT scan with all 20 seeds in place is
used as a reference to verify the accuracy of the localisation of the seeds by BrachyView. The
comparison of the two will verify the successfulness of the co-registration method utilised for
the coordinates systems of BrachyView and the CT data set.
The detector and pinhole collimator were aligned using an active seed directly above the
pinhole collimator and altering its position until its projection fell on the central pixel. A similar
process was used to align the pinhole camera with the phantom, this time with the seed
placed in the D2 position of the PMMA phantom and adjusting its position using the high
precision stepper motor. The coordinate system of the gamma camera (x, y, z) with its origin
defined as the pinhole. The high precision stepper motor translates along the Y axis of this
system.
The datasets from the BrachyView and the CT were co-registered using a point-to-point
method. A new origin has to be selected at a point where both the datasets can be
represented by an appropriate rigid shift and rotational transformations. This will be at the
midpoint of the line between the two markers which can be easily identified in both data sets.
The seeds in positions B2 and F2 (the outermost seeds in the phantom) were chosen as the
markers in this study. The coordinates of all the seeds were calculated with respect to the
registered origin.
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The effects of seed misplacement on the dosimetry were assessed via TG-43 based
calculations performed on the experimental brachytherapy seed plan. These dose
calculations used the positions of the seeds determined by the BrachyView and the CT. To
determine the effects of localisation discrepancies, several comparison studies were carried
out, including 2D Isodose Comparisons (2DIC), 2D dose difference colour-wash and dose
volume histograms (DVH) of the CTV. The total treatment dose (after full decay) from all seeds
were superimposed on 700x700 pixel grid (representing a 7x7𝑐𝑚 2 field) to create the isodose
curves, following TG-43 guidelines. If the determined dose was within a ±5% range of the
prescribed dose, the pixel colour was changed to match the selected isodose colour.
Within every pixel location, the total dose calculated from using the CT seed distribution was
subtracted from the total dose from the seed distribution determined by the BrachyView to
create the 2D dose colour-wash plots. Using an adjustable dose discrepancy scale, a colour
value was selected for each pixel.

Three-Dimensional Reconstruction
This experiment is aimed to test the probe using a larger number of seeds (20 active seeds)
within a more clinically relevant scenario. Triangulation is used to calculate the coordinates
of the centre of mass of each seed, and the positions of the seeds within the phantom can be
reconstructed.
Triangulation is a conventional three-dimensional reconstruction technique, which uses two
dimensional projections of the object, to find 3D coordinates of the point of in terest. This
method requires at least two sets of projections for reconstruction. Triangulation is an
excellent tool for rigid 3D reconstruction and is relatively computationally efficient.
The back-projection method utilised, uses the 2D images generated by the incident gamma
rays from the seeds projected onto the sensor plane through the pinhole collimator. The
pinhole is defined as the origin of the camera frame (𝑋𝑐0 , 𝑌𝑐𝑜 ), the image of a 3D object (i.e.
I-125 seed) is projected through this pinhole, on a 2D detector plane. To make matters
simpler, the centre of mass (COM) of the seeds is taken to approximate their position,
ignoring at this stage, their orientation.
To mimic a triple chip Medipix detector each equipped with their identical corresponding
pinholes, the single chip is translated via a drive system. This allows for three projected
images of the COM which are then back projected through their respective pinholes, however
only two projections through the pinhole collimator at two di fferent positions are required to
perform the reconstruction.
A simple mathematical model was developed to represent the relationship between the
coordinates of the “3D point” 𝑃𝑐 in the pinhole camera frame (𝑋𝑐 , 𝑌𝑐, 𝑍𝑐 ) and its projection
𝑃1 onto the image plane (𝑥, 𝑦) (Figure 4.4). The equation below expresses the relationship
between (𝑋𝑐 , 𝑌𝑐, 𝑍𝑐 ) and (𝑥, 𝑦) by the focal length 𝑓𝑥 = 𝑓𝑦 = 𝑓 assuming no astigmatic
aberration in the system (square pixel size, square pixel array, cylindrical symmetry of the
pinhole):
𝑥=𝑓

𝑋𝑐
,
𝑍𝑐

𝑦=𝑓
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𝑌𝑐
𝑍𝑐

If the origin of the image coordinate system has shifted from the centre of the image plane,
the displacement (𝑠1 , 𝑠2 ) will be included in the projection equations (the parameter 𝑠𝑖 can
be used to represent any movement of the point 𝑃𝑐 relative to the pinhole):
𝑥=𝑓

𝑋𝑐
+ 𝑠1 ,
𝑍𝑐

𝑦=𝑓

𝑌𝑐
+ 𝑠2 ,
𝑍𝑐

𝑧 = 𝑍𝑐

The above relations can be reformulated, using projective geometry framework as:
(𝛼𝑥, 𝛼𝑦, 𝛼) 𝑇 = (𝑓𝑋𝑐 + 𝑠1 , 𝑓𝑌𝑐 + 𝑠2 , 𝑍𝑐 )𝑇 → 𝑃̅1 = H𝑃̅𝑐
Where 𝛼 = 𝑍𝑐 is the homogeneous scaling factor, H is the intrinsic conversion matrix
composed by the parameters which characterize the pinhole-image apparatus in the camera
frame.
This model was implemented in MATLAB with the intrinsic parameters set to the
experimental setup values. Using MATLAB algorithms in three-dimensional geometry, vector
lines are drawn from the seeds’ projections on the detector plane, through the pinhole for
each detector position. The three detector positions will produce three vector lines as
illustrated in Figure 4.5. Theoretically the coordinates of the intersection of these vector lines
will be the position of the seed, however in three-dimensional space, non-parallel lines do
not necessarily intersect. Therefore, a chord is extended in the closest path between vector
lines from detectors 1 and 2, and from detectors 2 and 3. The average of their midpoints is
considered as the position of the seed. The algorithm will also work using only two projections
and thus two projected lines, however the added vector lines improves the accuracy of the
system.
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Fig.4.4: Schematic representation of the BrachyView coordinate model and reconstruction method by triangulation.

Fig.4.5: The experimental setup of the PMMA phantom and the direction of detector translation with the BrachyView
coordinate system. Theoretical vector lines are drawn from an arbitrary seed through the pinholes.
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Results
The progressive needle implantation procedure is captured by BrachyView, the projections in
Figure 4.6 were obtained with the probe at its first position, corresponding to Y=0 mm.
Due to the scattering interactions in the phantom and the collimator, there is a noticeable
increase in background noise and a gradual increase in counts detected. The detector is easily
able to resolve the projections from all 20 implanted seeds, even with the increasing
background noise. The order of implantation of the needles and the positions of the seeds is
displayed in Table 4.1.

Order of
Implantation

Position
CIVCO™ LDR
17GA Grid

Needle #1

C2.0

0.44

SPACER

0.47

SPACER

0.45

Needle #2

E2.0

SPACER

0.46

spacer

0.45

SPACER

0.47

Needle #3

B3.0

0.45

SPACER

0.44

Needle #4

F3.0

0.45

SPACER

0.43

Needle #5

c3.5

0.47

SPACER

0.46

SPACER SPACER

0.45

Needle #6

d3.5

0.47

SPACER SPACER

Needle #7

D2.0

0.45

SPACER

Individual seed position in the needle and corresponding Air
Kerma Strength (U=μGy m2/h) – Uncertainty ±1%

0.47

0.44

SPACER

0.45

SPACER

0.46

SPACER

0.43

Tab.4.1: The seed positions within the needles and the order of implantation.

Fig.4.6: The projections captured by the pinhole camera highlighting the order of implantation intra-operatively.

As mentioned in the method, the experiment was carried out using a single detector placed
below a single pinhole, and translated along the Y direction to mimic the triple chip setup.
The projections are acquired at Y = -14 mm, Y = 0 (starting position) and Y = +14 mm, each
seed can be identified in all three images. Figure 4.7 shows three projections of the whole set
of seeds, with cross identifying the COM of each seed.
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Fig.4.7: The triple chip detector image is obtained by stitching projections acquired at each Y position. Using the lateral shift
of the detector (±14mm) and the seeds’ projections, the 3D positions of the seeds can be reconstructed.

By using the new origin, the midpoint between the two selected seed markers (B3 and F3)
the 3D reconstructed results from the CT and the BrachyView can be compared. These
positions are superimposed in the graphs in Figure 4.9.

Fig.4.8: A transversal CT slice showing all 7 needles implanted, this is taken at the theoretical depth of the prostate base.
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(a)

(b)
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(c)
Fig.4.9: The 3D reconstructed positions of the seeds using the BrachyView and the CT are shown in orthogonal projections,
in (a) top view (corresponding to XY), (b) front view (corresponding to XZ), and (c) side view (corresponding to YZ).

To better demonstrate the accuracy of the seed localisation, an additional visualization
method has been utilised, a reconstruction of the seed population using the COM of the seeds
resolved by the BrachyView. The model is based on the known shape and dimension of the
seeds. The three-dimensional CT images are co-registered with the reconstructed images
from the BrachyView. A high selective CT number is applied to the reconstructed CT images
in order to segregate the high-density titanium cells of the seeds.
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Fig.4.10: The co-registered images from the BrachyView and the CT scans, reconstructe d in 3D.

The isodose calculations of the seeds localised by the BrachyView and the CT at depths y = 10
mm, y = 15 mm and y = 20 mm are shown in Figure 4.11 (a), (b) and (c) respectively. The
BrachyView isodose curves are marked red and the CT isodose curves are marked blue. The
DVH plot in Figure 4.12 compares BrachyView and CT determined seeds positions for a 50Gy
prescription dose to Prostate CTV. As above the red curve represents the DVH for the seeds
localised by BrachyView and blue curve for the CT determined seed locations.

Fig.4.11: Comparison of the Isodose curves, calculated based on the locations of the seeds determined by BrachyView and
CT. These isodose curves are taken at three depths at y = 10 mm, 15 mm and 20 mm in respect to the BrachyView coordinate
system.
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Fig.4.12: Dose Volume Histogram plot based of BrachyView and CT determined seed positions for a 50 Gy prescription
dose.

An increase the in the background counts is expected with an increased number of
implanted seeds. A subtraction method has been developed to account for this: after each
needle is implanted, the frame (𝑓) is recorded by the detector and a new frame (𝑓 + 1) is
initiated. To clearly identify the seeds implanted during frame (𝑓 + 1), the count map from
(𝑓) is subtracted from this frame, resulting in the net pixel count map. This subtraction
method follows the implantation procedure, and maintains an almost constant background
signal despite the increase in the number of seeds. The developed algorithm is as follows:
𝑔(𝑖, 𝑗) = 𝑓𝑛+1 (𝑖, 𝑗) − (𝑓𝑛 (𝑖, 𝑗) +

𝑓𝑛 (𝑖, 𝑗)
× 𝑡𝑛+1 )
𝑡𝑛

Where 𝑓𝑛+1 (𝑖, 𝑗) represent the 256 × 256 pixel frame array at the 𝑛𝑡ℎ frame number, 𝑡𝑛
represents the acquisition time of the 𝑛𝑡ℎ frame and 𝑔(𝑖, 𝑗) is the outputted subtracted
frame.
The background signal will start to deteriorate the reconstructed image, with an increasing
number of seeds implanted. Figure 4.13 demonstrates a linear increase in the background
pixel counts per pixel per minute as more seeds are implanted. By extrapolating this trend in
Figure 4.14, it can be estimated that the background to signal ratio will become a notable
problem at around 30 implanted seeds. At this point the subtraction algorithm will be
needed to maintain a steady signal to background ration for seed reconstruction.
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Fig.4.13: Increasing background signal with number of seeds, much improved signal to noise ratio with Background
subtraction.

Fig.4.14: Linear extrapolated background noise demonstrating the need of the subtraction algorithm for more than 30
implanted seeds
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Chapter Five: Gel Phantom Experiment
The following chapter describes the extension of the methodology developed and described
in Chapter 4 to a gel phantom which better represent the elasticity and deformability of the
soft tissues involved in LDR brachytherapy. In this work, the candidate has participated in the
experiments and preparation of the setup.
The results of this experiment have been published on:
Alnaghy, S., Cutajar, D., Bucci, J., Enari, K., Safavi-Naeini, M., Favoino, M., Tartaglia, M.,
Carriero, F., Jakubek, J., Pospisil, S., Lerch, M., Rosenfeld, A. and Petasecca, M. (2017).
BrachyView: Combining LDR seed positions with transrectal ultrasound imaging in a prostate
gel phantom. Physica Medica, 34, pp.55-64.

Materials and methods
The original triple chip set up of the BrachyView probe was constructed for this experiment.
The probe has a total length of 80mm and consists of a 1mm think cylindrical tungsten
collimator enclosing a triple chip Timepix detector. The tungsten tube features three single
cone pinholes located 22.5mm apart from each other with and opening of 112°, a physical
diameter of 0.5mm and a channel length of 0.1mm, illustrated in Figure 5.1. A 4.5mm gap
exists between the each Timepix sensor and its corresponding pinhole. Each chip consist s of
256 × 256 pixels which give a total imaging area of 256 × 768 pixels. The PCB protruded the
tungsten shell where the Fitpix readout system was made. A thin layer of Kapton was used to
water seal the probe and to reduce the low-energy electron backscatter from the tungsten
surface.

Fig.5.1: Design of BrachyView probe, incorporating three Timepix detectors housed in a 1 mm thick tungsten tube .

The phantom used in this experiment was CIRS tissue equivalent ultrasound prostate
phantom. The CIRS Model 053-I training phantom specifically developed for practicing
permanent seed implantation procedures. This phantom features a transparent gel to permit
visualization of the orientation the probe and the implanted needles. The phantom was
mounted on a PMMA stand which allows for position adjustment while creating a rigid setup
to prevent mechanical movement during the treatment procedure. The experimental setup
is demonstrated in Figure 5.2. The experiment was based on a clinical protocol for LDR
brachytherapy treatment. The TRUS was first used to find the base of the prostate volume
then it was stepped 5 mm deeper beyond the base, which defined the origin of the TRUS
system. The entire prostate volume was imaged using 2.5mm slice increments until the
phantom was completely covered.
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There were 11 needles loaded with 30 active 0.4 mCi I-125 source, they were implanted into
the prostate phantom with the aid of the TRUS guidance. Figure 5.3 shows the treatment plan
utilised for this experiment. After the insertion of each needle the TRUS probe was removed
and the BrachyView was inserted in the phantom cavity. Acquiring an image after each needle
insertion allows for understanding cumulative counts of the implanted seeds. The BrachyView
probe was carefully placed in the cavity such that the middle pinhole was aligned with the
middle of the prostate volume. After all 30 seeds were implanted, a full CT scan of the setup
was performed with the BrachyView probe inserted, using the Philips Brilliance CT system.

Fig 5.2: Experimental setup showing CIRS tissue equivalentultrasound prostate phan - tom and TRUS system placed on PMMA
holder.

Fig.5.3: Varian Medical Systems VariSeed treatment plan, (a) Needle loading table, showing planned seed positions for 30
0.400 mCi 125I seeds. (b) 2D grid of needle implant, showing plane location of first seed.

The basis of the reconstruction system remains the same for localising the position of the
implanted seeds in the 3D. Using the triple chip mechanism, there is no need for translation
of the probe and the projections are acquired simultaneously through 3 separate pinholes as
illustrated by Figure 5.4. However, the COM of the seeds is calculated using a cluster
recognizing algorithm, which is an improvement on manual selecti on of the seeds. The origin
of the BrachyView system is selected as the corner of the first Timepix chip. Three vector lines
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can be acquired from each seed projection; however, a minimum of two vector lines is
sufficient to perform triangulation.
To find the minimum distance to all the vector lines, firstly an arbitrary point 𝑃 with
coordinates (x, y, z) is considered. The perpendicular distance from the acquired vector lines
𝑑𝑛to point 𝑃 is determined by:
|⃗⃗⃗⃗⃗
ℎ𝑛| =

⃗⃗⃗⃗⃗⃗⃗⃗⃗
𝐵𝑛 𝑃 × ⃗⃗⃗⃗⃗
𝑑𝑛
| ⃗⃗⃗⃗⃗
𝑑𝑛 |

By summing all these perpendicular distances, a function 𝑓(𝑥, 𝑦, 𝑧)can be formed. Thus by
minimizing 𝑓 the intersection of all back projected line in 3D space can be determined.
𝑛

𝑓(𝑥, 𝑦, 𝑧) = ∑ ⃗⃗⃗⃗⃗
ℎ𝑛
𝑖=1

Fig.5.4: Conceptual view of reconstruction method for 125I seeds within a prostate volume.

The Nelder-Mead method is implemented here, to find the point with the smallest distance
from all the vector lines. This method only uses function evaluations (i.e. no derivatives) thus
is an iterative optimization technique starting at point 𝑃. It utilizes a Simplex, which is a
polytope in N dimensions with N+1 vertices, in the case of 3D Cartesian coordinates system,
is a tetrahedron which changes its shape until a minimum solution is located.
A software application has been developed specifically for the BrachyView system, which
implements the reconstruction algorithm automatically. The need for manual selection of the
seeds projections is eliminated, which had proved to be a tedious and time consuming task.
The 3D interactive platform allows for the visualization of the treatment volume the
brachytherapy seeds in a single coordinate system. The software was developed using
Microsoft Visual studios and QT Creator in C++. The application is capable of rendering a 3D
volumetric reconstruction of the prostate, using raw ultrasound slices. It utilizes external C++
libraries, Insight Segmentation and Registration Toolkit (ITK) and Visualization Toolkit (VTK),
which are open source software tools for image analysis, 3D reconstruction and visualization
for medical imaging purposes.
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The raw ultrasound images are taking from the TRUS system as a bitmap file, and the
application recognizes and extracts the prostate volume as a Region Of Interest (ROI). The
gridlines overlaid by the TRUS software are removed and are replaced by using linear
interpolation of the surrounding pixels. This process is necessary prior to the reconstruction,
as the gridlines would appear to be planes through the prostate volume. The entire process
is automated and requires no input from the user. Next a smooth 3D reconstruction of the
TRUS images is acquired, by stacking the 2D ultrasound images in the z direction and
performing linear interpolation. The dimensions of the LDR I-125 seeds are used to create a
3D representation of the sources. By loading the reconstructed positions of the seeds in the
TRUS coordinates system, a 3D image the prostate with the LDR seeds overlaid is constructed.
At the end of the implantation process, a full CT of setup was performed using a Philips
Brilliance CT system. A slice thickness of 1mm was selected with an overlap of 0.5mm. To
reduce the streaking artefacts from the tungsten collimator, Metal Artefact Reduction for
Orthopaedic Implants (O-MAR) was selected. The CT scan is an accurate tool for comparison
of the reconstruction data from the BrachyView, and is used as a reference. The CT data was
also used to co-register all three coordinate systems of the CT, BrachyView and TRUS.
The origin of the CT coordinate system is the bottom right corner of the imaging volume, the
origin of the BrachyView coordinate system is the corner of the first Timepix chip and the
origin of the TRUS coordinate system is located 5mm from the base of the prostate and on
the bottom right edge of the prostate volume. The positon of the BrachyView probe and the
TRUS system was found relative to the origin of the CT coordinate system. Thus vectors were
drawn from the origin of these systems, to the origin of the CT coordinate system, and were
used to transform the BrachyView reconstructed seed positions into the TRUS coordinate
system. The same method was used to transform the seed positions form the CT in the TRUS
system. The CT data was also used to assess the accuracy of the 3D reconstruction of the
prostate volume using the 2D ultrasound slices. Figure 5.5 illustrates a co-registration of all
three coordinate systems.

Fig.5.5: shows CT, BrachyView and TRUS coordinate systems based on experimental setup.
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Results
The seed positions, determined by the CT images and reconstructed via BrachyView data, are
plotted in Figure 5.6 in the three planes of the BrachyView coordinate system. Figure 5.7
illustrates a 3D scatter graph of the seed locations reconstructed by the CT and the
BrachyView. Figure 5.8 shows screen shots of the developed software visualization interface
at various viewing angles, displaying a 3D reconstructed prostate volume, from the
ultrasound slices via the TRUS. Reconstructed LDR seeds from the BrachyView and the CT data
set are co-registered on the 3D TRUS prostate volume (TRUS coordinate system).

(a)
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(b)

(c)
Fig.5.6: 2D scatter plots of reconstruct e d seed positions from BrachyVie w system and CT determine d see d
positions co-registere d in the BrachyVie w coordinate system on each coordinat e pl ane. (a) front view
(corresponding to XZ) , (b) side view (corresponding to YZ) and (c) top view (corresponding to XY).
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Fig. 5.7: 3D scatter plot of reconstructed seeds from BrachyView and CT determined seed positions.

Figure 5.8: Screen shot of software interface depicting 3D prostate model reconstructed from US images with reconstructed
seed positions from both the BrachyView and CT data set co-registered into a single coordinate system.
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Chapter Six: Discussion
PMMA Phantom Experiment
Despite the use of a single detector and a stepper motor to mimic the presence of three
devices, the BrachyView system is able to reconstruct seed positions using the triangulation
method. In the 20 seeds experiment, the seeds were found within the PMMA phantom with
an accuracy of 1-2mm as compared with the CT scan within a distance of 6cm from the
collimator. The multi-seed plan imitated a more clinically relevant case in respect to the
feasibility study performed by Petasecca et al., to demonstrate the capabilities of BrachyView
in resolving multiple seeds in real time with sub-millimeter accuracy. Although the setup is
still short of a full clinical LDR brachytherapy plan (between 60-120 seeds), the superior
resolution of the BrachyView will allow localisation of the most distal seeds from the pinhole
(50-60mm).
In this experiment a single detector was translated via a stepper motor to mimic a triple chip
setup. This introduces a systematic error in determining the position of the pinhole which is
used to localise the seeds in the phantom, therefore sabotaging the overall accuracy of the
reconstruction. A fully functional multiple chip assembly will allow for a rigid coordinate
system and remove uncertainties introduced by a moving detector. This will also obviate th e
need for complicated alignment methods, which will further reduce uncertainties in the
system.
BrachyView is aimed to be used during the implantation procedure, as an intraoperative
imaging modality, whereby seeds can be imaged during the treatment bef ore they have been
dropped by the needle. This will allow for online monitoring of the dose distribution and thus
active corrections on the location of the seeds with in the prostate volume. The BrachyView
system is not capable of performing day 30 post-implant dosimetry, as the seed activity would
be considerably reduced, and resolving the seeds would be impossible due to poor signal to
background ratio.
A background subtraction method was developed to account for accumulative background
counts which would otherwise saturate the signal. Using this algorithm, it was hypothesized
that background subtraction would be necessary after 30 implanted seeds, as the signal to
background ratio will become significantly poor. The subtraction method will require an
iterative needle implantation procedure and thus cannot be implemented in a post-implant
dosimetry, as resolving all the implanted seeds would prove very difficult. Although beyond
the scope of this experiment, this simple methodology demonstrates the capabi lities of the
BrachyView to localise sources in a full-size clinical implant. The flat lead collimator is
responsible for the current signal to background ratio, this problem is addressed with a
cylindrical tungsten collimator which allows for better lateral shielding from the phantom or
the patient.
Dose calculation using TG-43 have shown the importance of seed accuracy and the outcomes
of dose variations due to seed misplacement. The isodose plots show variations due in dose
distributions between the BrachyView and CT dataset. The largest discrepancies are at the
slices where seed position variations are high between the two data sets. The dose histogram
showed 8.61% deviation between the BrachyView and CT datasets, despite seed position
discrepancies of 1-2mm.
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The Air KERMA strength of the seeds was measured by a well chamber at the St. George
hospital. This procedure was performed post implantation, and ensured a uniform dose
delivery to the phantom. The measured values ranged from 0.426 – 0.481 𝜇𝐺𝑦 𝑚2 ℎ −1. The
activity of each individual seed was used to calculate the overall dose distribution.
In this experiment, a rigid PMMA phantom was used for seed implantation, and thus the coregistration of the two data sets was rigid and quite simple. A point to point co-registration is
sufficient for the purposes of this study. However, in clinical conditions Ultrasound images
are acquired in the lithotomy position via a rectal probe and the CT images are taken with the
patient laid down on the CT couch. To allow for a rigid reconstruction in a clinical setting, a
mechanical co-registration is under investigation, one which features the TRUS probe and
BrachyView on opposite halves of the stepper unit and thus sharing a coordinate system.
Another proposed method is the use of fiducial markers that can be picked up by the
ultrasound images that will guide the co-registration.

Gel Phantom Experiment
The new improved BrachyView probe features a triple chip Timepix detector enclosed in a
cylindrical tungsten collimator. In this experiment 30 active seeds were implanted in a gel
prostate phantom following a realistic implantation process. BrachyView was used in
conjunction with a TRUS probe to localise the implanted seeds with respect to the anatomical
features resolved by the ultrasound images. CT images of the whole setup were acquired for
a set standard. The BrachyView probe was able to successfully reconstruct the locations of all
30 implanted seeds. A maximum discrepancy of 1.78mm was observed betw een the
BrachyView and CT determined seed positions. It was determined that 75% of the BrachyView
resolved seeds lay within 1mm of the CT determined positions. Each component of the
discrepancies between CT and BrachyView was examined, with Z direction discrepancies all
within the submillimeter range, the X direction discrepancies showed 68% within 1mm and
the largest differences were found in the Y direction. The sources of error in the
reconstruction are determined to be the calculated position of the pinholes relative to the
origin (corner of the first Timepix chip), and the ability to accurately locate the COM of the
seeds. An error of 0.1mm in the position of the pinhole will result in an uncertainty of ±
0.56mm in the X or Y direction, this effect is smaller in the Z direction ± 0.27mm.
This calculation is based on a model determined in the previous study conducted
by Petasecca et. al.
The CT determined seed locations were found by defining the centre of the each
seed from the CT slices. The slice width used to image the seeds was 1mm which
limits the accuracy of determining the centre of the seeds particularly in the Y
direction (along their length).
The physical compression of the gel phantom was obse rved by the insertion of the probes,
which contributes to the movement of the already implanted seeds. The non-rigid phantom
changes shape in the process of inserting and removing the BrachyView and the TRUS probes,
this is most relevant in the Y direction. This replicates a clinical scenario where the soft tissue
of the internal organs is compressed due to the implantation of the needles, even without
removing the TRUS probe. This problem can be addressed by inserting a thin plastic shell, into
which the probes can slide in and out without deforming the internal organs.
By stacking the ultrasound slices of the prostate, the volume of the gel phantom was
successfully reconstructed. The internal features of prostate, the urethra and seminal
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vesicles, and the outline of the organ were clearly visible in the visualisation software. The
rigid transformation of the BrachyView and CT coordinate systems into the TRUS coordinate
system was successfully achieved. The 30 implanted seeds were located within the prostat e
volume of the gel phantom.
BrachyView is a powerful tool for Quality Check which allows the localisation of Permanent
Brachytherapy seeds implanted within the prostate. It requires no extra time for image
acquisition and is performed within the operating room thus the patient does not need to be
moved. A day 0 post-implant CT is not required and thus no additional dose is delivered to
the patient and the uncertainties that arise with the use of CT can be avoided.
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